SunTrust analyst Bruce Nudell kept his Buy rating and $110 price target on Medtronic after traveling with its management recently on meetings with investors, saying the discussions were upbeat in terms of confidence about the company's "business momentum and tightened financial controls". The analyst says the management was especially "excited" about the impact of StealthStation navigation that enables the Mazor system to have on the "spinal implant market share and stickiness". Nudell adds that the company was also "enthusiastic" about its Diabetes franchise growth of over 20% this year.